Abbott Hoists Forecast Sails Higher Despite Infant Formula, Inflation, Exchange Headwinds
Executive Summary
Although sales of infant formula and other pediatric nutritionals were down more than 20% in US and more than 13% worldwide during Q2 on an organic measure – excluding a currency exchange impact – Abbott reports 14.3% overall sales growth to $11.3bn.
You may also be interested in...
Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’
Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
US Q2 Consumer Health Earnings Preview: Horizon Brightens Beyond Current Questions, Challenges?
Consumer health product firms’ vistas include challenges of supply chain disruptions lingering from pandemic’s impact as well as potential for marketplace restrictions as additional varieties of the novel coronavirus spread. Clouds also include shifts in consumer spending, increases in costs caused by inflation and foreign exchange headwinds as the value of the US dollar strengthens against other currencies.